Roche is acquiring Poseida Therapeutics, a biotech developing allogeneic cell therapies for cancers and immunological indications. The two companies have been partners in hematological malignancies since 2022.
The progress of gene therapies continues to be stymied by safety risks associated with the viruses used to deliver them. Takeda Pharmaceutical is partnering with Poseida Therapeutics in a bet that the biotech’s non-viral technologies could offer a safer alternative.
A new independent study from Phyx Primary Care’s Innovation Lab points to measurable improvements in physician burnout, documentation efficiency, and key VBC metrics among primary care practices.
The two companies will collaborate to ensure timely cell collection, transport and delivery for autologous CAR-T cell therapies in cancers.
The company has initiated a Phase II registration trial of a CAR-T that could compete against bluebird and Janssen. CEO Eric Ostertag noted it will dose the first patient in May or June.